Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2002

View Archived Issues

Dose-dependent improvement on rotigotine CDS in Parkinson's patients

Altocor filed for European marketing approval

Name change for inhalation technology company

Novel therapy to reduce or eliminate insulin dependence proves effective in NOD mice

Compounds with anticonvulsant activity prepared and tested at Arzneimittelwerk Dresden

Lead Androgenics compound blocks androgen receptor activation at an early step

CKD-732 examined for pharmacokinetic and metabolic profile in vitro and in vivo

All four components of PHY-906 necessary for biological activity as chemotherapy adjuvant

Small-molecule inhibitors of FAH designed at Bayer as potential agents for NSCLC

Small-molecule GnRH antagonist with good oral bioavailability presented at AACR meeting

Takeda presents new orally active antitumor agent for HER2-positive cancers

CTLA4-Ig cleared to enter phase I/II trial in ITP

Phase III trial of Affinitac in combination with Gemzar/cisplatin in NSCLC

Aquavan completes phase I study, safely achieves loss of consciousness

Ampligen evaluated in two new HIV/AIDS trials

Patient enrollment completed in phase II trial of interferon omega in chronic hepatitis C

Tularik presents first-quarter 2002 results

Broad-spectrum antimicrobial agents described by Chiron

Oxazolidinones patented by Abbott for bacterial infections, etc.

Tricyclic protein farnesyltransferase inhibitors with antiproliferative activity

New Chiron compounds reportedly useful for angiogenesis-related conditions

Roche designs new p38 kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.